Cassava Announces Closure of U.S. Department of Justice Investigation
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.
As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC’s allegations.
The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.
“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” said Richard J. Barry, President and Chief Executive Officer of Cassava.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications.
For more information, please visit: https://www.CassavaSciences.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sixth Consecutive Season Exceeds Expectations: Roku (ROKU.US) Revenue Hits $1.5 Billion, Beats Forecasts; $22 Billion Acquisition Remains Unresolved
Roku (ROKU.US) released its Q3 2026 financial results after the U.S. stock market closed on Monday.
Overnight US Stock Market | Nasdaq surged and then pulled back, the three major indexes were mixed; Marvell Technology (MRVL.US) fell 12.7%
At the close, the Dow Jones Industrial Average rose by 213.67 points, or 0.41%, to 51,983.98 points; the S&P 500 Index fell by 38.67 points, or 0.51%, to 7,541.40 points; and the Nasdaq Composite Index dropped by 272.68 points, or 1.07%, to 25,164.32 points.
Meta (META.US) Plans to Issue at Least $20 Billion in Cross-Border Investment-Grade Bonds, Marking Its First Foray into the Euro Bond Market
According to sources familiar with the matter, Meta Platforms is considering raising at least $20 billion through an investment-grade cross-border bond issuance to support its expanding artificial intelligence investment plans.
Palantir (PLTR.US) Q3 revenue surged 96% year-on-year; U.S. commercial business revenue surpassed government business for the first time
Artificial intelligence data analytics company Palantir announced its financial results for the third quarter of 2026 on Monday.
Crypto prices
More
